Allspring Global Investments Holdings LLC grew its position in Revvity Inc. (NYSE:RVTY – Free Report) by 29.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,259,286 shares of the company’s stock after buying an additional 507,674 shares during the period. Allspring Global Investments Holdings LLC owned 2.02% of Revvity worth $198,636,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in Revvity by 5.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock worth $832,693,000 after purchasing an additional 434,570 shares during the period. Janus Henderson Group PLC grew its position in shares of Revvity by 7.0% during the 4th quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock worth $789,595,000 after buying an additional 533,912 shares during the period. Morgan Stanley grew its position in shares of Revvity by 29.6% during the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock worth $275,202,000 after buying an additional 650,083 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Revvity by 22.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,116 shares of the company’s stock worth $252,727,000 after buying an additional 486,159 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Revvity by 15.7% during the third quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock worth $223,816,000 after buying an additional 346,313 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.
Revvity Stock Up 0.3%
NYSE:RVTY opened at $111.65 on Friday. The stock has a 50-day simple moving average of $103.38 and a 200 day simple moving average of $99.08. Revvity Inc. has a 52-week low of $81.22 and a 52-week high of $118.30. The company has a market cap of $12.46 billion, a PE ratio of 53.42, a PEG ratio of 2.19 and a beta of 1.09. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72.
Revvity Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Friday, July 17th. Revvity’s dividend payout ratio is currently 13.40%.
Analyst Ratings Changes
Several equities analysts recently weighed in on RVTY shares. JPMorgan Chase & Co. cut their price objective on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Revvity in a research report on Wednesday. Weiss Ratings raised Revvity from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. Stifel Nicolaus reduced their price target on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Finally, Robert W. Baird set a $117.00 price objective on Revvity in a research note on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $108.92.
Get Our Latest Stock Analysis on RVTY
About Revvity
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Featured Stories
- Five stocks we like better than Revvity
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
